Wedbush Initiates Coverage on EIKN (NASDAQ:EIKN)

Analysts at Wedbush began coverage on shares of EIKN (NASDAQ:EIKN - Get Free Report) in a note issued to investors on Thursday, MarketBeat reports. The firm set an "underperform" rating and a $7.00 price target on the stock. Wedbush's price target would suggest a potential downside of 52.99% from the company's current price.Separately, Wall Street Zen upgraded shares of EIKN to a "hold" rating in a research note on Monday, February 16th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Sell" and a consensus target price of $7.00.Check Out Our Latest Research Report on EIKNEIKN Price PerformanceShares of EIKN stock opened at $14.89 on Thursday. EIKN has a 52-week low of $13.28 and a 52-week high of $17.40. About EIKN (Get Free Report)We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.Featured StoriesFive stocks we like better than EIKNREVEALED: Something Big Happening Behind White House DoorsMAJOR BUY ALERT: Mar-a-Lago/Trump/ElonALERT: Drop these 5 stocks before the market opens tomorrow!Why the Smart Money Is Looking Beyond Single-Metal StoriesRead this or regret it foreverThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in EIKN Right Now?Before you consider EIKN, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EIKN wasn't on the list.While EIKN currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here